News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–14
Matches
14
Sources here
9
Companies here
1
Search results Stored financial headlines

Active search

14 matching headlines

Ticker or company: ELOXMain company stories
Clear
Latest

Stock Titan Deals and strategy

Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate

Investment entities affiliated with Samsara BioCapital and Srinivas Akkaraju have reported significant beneficial ownership in Eloxx Pharmaceuticals (ELOX). Dr. Srinivas Akkaraju holds 9.99% of the common stock, while each Samsara BioCapital-affiliated entity owns 5.0%. This includes common shares and Pre-Funded Warrants subject to a 9.99% Beneficial Ownership Blocker.

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
Just inNext headlines
Stock Titan Deals and strategy Main company 🇺🇸 United States

Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 9.91% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. (ELOX) through a Schedule 13G filing. As of June 30, 2026, the reporting persons beneficially own 400,000 shares, with shared voting and …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

LifeSci Capital Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $40

LifeSci Capital has reiterated its Buy rating for Eloxx Pharmaceuticals (ELOX.US) and maintained its target price at $40. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Stock Titan Earnings Main company 🇺🇸 United States

Eloxx Plans Phase 2b Alport Trial in Q3 After ~$66M Offering

Eloxx Pharmaceuticals reported its second-quarter 2026 financial results, highlighting a significant strengthening of its capital position with $62.0 million in cash after a $66.0 million public offering. The company plans to initiate a Phase 2b clinical trial for exaluren in nonsense mutation Alport syndrome …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
PR Newswire Earnings Main company 🇺🇸 United States

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Eloxx Pharmaceuticals reported strong second-quarter 2026 financial results, highlighted by a $66.0 million public offering and uplisting to Nasdaq, significantly bolstering its balance sheet. The company is advancing its lead product candidate, exaluren, with a Phase 2b clinical trial for nonsense mutation Alport syndrome …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
seekingalpha.com Earnings Main company 🇺🇸 United States

Eloxx Pharmaceuticals GAAP EPS of -$0.66

* Eloxx Pharmaceuticals press release [https://seekingalpha.com/filing/309938915] (ELOX [https://seekingalpha.com/symbol/ELOX]): Q2 GAAP EPS of -$0.66. * As of June 30, 2026, the Company had cash and cash equivalents of $62.0 million, which includes approximately $58.3 million in net proceeds from the June 2026 public offering. The …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Eloxx Pharmaceuticals reports Q2 2026 net loss $4.5M, $62.0M cash after $66.0M offering

Eloxx Pharmaceuticals reported a net loss of $4.5 million for Q2 2026 and held $62.0 million in cash after a $66.0 million public offering and uplisting to Nasdaq. The company plans to initiate a Phase 2b trial for exaluren in Alport syndrome in Q3 …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
Investing.com Canada Market update Main company 🇺🇸 United States

Form 8K Eloxx Pharmaceuticals Inc For: 11 August By Investing.com

This article reports that Eloxx Pharmaceuticals Inc. filed a Form 8K on August 11. The brief entry provides the company name, the filing date, and a stock performance indicator showing ELOX up 12.82%. The article primarily serves as a notice of the regulatory filing.

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Eloxx Pharmaceuticals, Inc. 2Q 2026: Net loss $4.5M, EPS $(0.66) — 10-Q Summary

Eloxx Pharmaceuticals, Inc. reported a net loss of $4.5 million, or $(0.66) per share, for the second quarter of 2026, widening from a $1.9 million net loss in 2Q 2025. The company had no license or product revenue for the quarter. Key business highlights …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Eloxx Pharmaceuticals Ord Shs (ELOX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Eloxx Pharmaceuticals Ord Shs (ELOX), indicating a "Buy" trend based on one analyst's rating. The target price suggests a significant upside, though specific EPS, revenue, and net profit figures are not yet disclosed. The forecast emphasizes that …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
nasdaq.com Earnings Main company 🇺🇸 United States

Biotech Stocks At 52-Week Highs - ANGO, ANIK, ELOX, YARW, PLSE

(RTTNews) - The following biotech stocks reached a 52-week high on August 3, 2026, driven by key catalysts such as upcoming quarterly reports or the initiation of clinical trials. AngioDynamics Inc. (ANGO) AngioDynamics, a medical technology company, specializes in developing technology to improve vascular …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
MarketBeat Balance sheet Main company 🇺🇸 United States

Eloxx Pharmaceuticals (ELOXD) Financials 2026 - Income Statement and Balance Sheet

This article provides a detailed financial analysis of Eloxx Pharmaceuticals (ELOXD), focusing on its income statement, balance sheet, cash flow, and key financial ratios through 2026. The company remains pre-revenue, with significant operating losses and reliance on equity financing, leading to substantial shareholder dilution. …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Eloxx Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELOX

This article provides a revenue breakdown for Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) as listed on TradingView. It indicates that the market is closed with no trades and lists various financial and community features available for the company's stock. The content focuses on navigating the …

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

Guggenheim Initiates Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Announces Target Price $43

Guggenheim has initiated coverage on Eloxx Pharmaceuticals (ELOX.US) with a Buy rating. The firm has set a price target of $43 for the company's stock. This indicates a positive outlook from Guggenheim regarding Eloxx Pharmaceuticals' future performance.

ELOX main company
Sharemaestro market context Stored weekly price path 10 weeks +38.8% · Next-week setup positive 58.3% ELOX stored weekly price path from 12 Jun 2026 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context